Get the Stockscreener App
1.79
0.56%
-0.01
Pre-market:
1.83
0.04
+2.23%
Tscan Therapeutics Inc stock is traded at $1.79, with a volume of 247.60K.
It is down -0.56% in the last 24 hours and down -12.25% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.80
Open:
$1.81
24h Volume:
247.60K
Relative Volume:
0.55
Market Cap:
$101.30M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.00
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-13.94%
1M Performance:
-12.25%
6M Performance:
-68.82%
1Y Performance:
-73.32%
1-Day Range:
$1.725
$1.83
1-Week Range:
$1.711
$2.095
52-Week Range:
$1.711
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
880 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.79 | 101.30M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Weekly Investment Analysts’ Ratings Changes for TScan Therapeutics (TCRX) - Defense World
Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position - TipRanks
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones - Investing.com India
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones By Investing.com - Investing.com South Africa
Head to Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Novavax (NASDAQ:NVAX) - Defense World
TScan Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Q2 EPS Estimate for TScan Therapeutics Lowered by Analyst - Defense World
Wedbush Equities Analysts Cut Earnings Estimates for TCRX - Defense World
Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World
Barclays Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 (NASDAQ:TCRX) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics price target lowered to $3 from $14 at Barclays - TipRanks
Needham & Company LLC Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns Outperform Rating from Wedbush - Defense World
H.C. Wainwright maintains $15 target on Tscan shares By Investing.com - Investing.com Canada
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains $15 target on Tscan shares - Investing.com India
Breaking Down TScan Therapeutics: 4 Analysts Share Their Views - Benzinga
TScan Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million -March 05, 2025 at 04:54 pm EST - Marketscreener.com
Tscan Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
TScan Therapeutics reports Q4 EPS (30c), consensus (28c) - TipRanks
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics, Inc. SEC 10-K Report - TradingView
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
TScan Therapeutics (NASDAQ:TCRX) Stock Price Down 11.9% – Here’s What Happened - Defense World
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference - The Manila Times
How Will TScan's Cancer Therapy Pipeline Impress Investors at Major Healthcare Conference? - StockTitan
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Inside TScan's Revolutionary TCR Cell Therapy Pipeline: CEO Conference Presentation Revealed - StockTitan
abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting (NASDAQ:TCRX) - Seeking Alpha
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - MarketBeat
Heck Capital Advisors LLC Takes $61,000 Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Armenian Reporter
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal year - MSN
TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - MSN
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC - Defense World
State Street Corp Has $3.77 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):